DE60237969D1 - Menschliche antikörper gegen timp-1 - Google Patents

Menschliche antikörper gegen timp-1

Info

Publication number
DE60237969D1
DE60237969D1 DE60237969T DE60237969T DE60237969D1 DE 60237969 D1 DE60237969 D1 DE 60237969D1 DE 60237969 T DE60237969 T DE 60237969T DE 60237969 T DE60237969 T DE 60237969T DE 60237969 D1 DE60237969 D1 DE 60237969D1
Authority
DE
Germany
Prior art keywords
timp
human antibodies
antibodies against
fibrosis
against timp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237969T
Other languages
English (en)
Inventor
Clark Pan
Andreas M Knorr
Michael Schauer
Claudia Hirth-Dietrich
Sabine Kraft
Barbara Krebs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Bayer Corp
Original Assignee
Morphosys AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG, Bayer Corp filed Critical Morphosys AG
Application granted granted Critical
Publication of DE60237969D1 publication Critical patent/DE60237969D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
DE60237969T 2001-04-24 2002-04-24 Menschliche antikörper gegen timp-1 Expired - Lifetime DE60237969D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28568301P 2001-04-24 2001-04-24
PCT/US2002/012801 WO2002086085A2 (en) 2001-04-24 2002-04-24 Human timp-1 antibodies

Publications (1)

Publication Number Publication Date
DE60237969D1 true DE60237969D1 (de) 2010-11-25

Family

ID=23095281

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237969T Expired - Lifetime DE60237969D1 (de) 2001-04-24 2002-04-24 Menschliche antikörper gegen timp-1

Country Status (9)

Country Link
US (6) US7091323B2 (de)
EP (1) EP1381631B1 (de)
JP (2) JP4406206B2 (de)
AT (1) ATE484522T1 (de)
AU (1) AU2002307494A1 (de)
CA (1) CA2445168A1 (de)
DE (1) DE60237969D1 (de)
HK (1) HK1061699A1 (de)
WO (1) WO2002086085A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US20060154245A1 (en) * 1999-04-09 2006-07-13 Rigshospitalet Method for detecting, screening and/or montoring a cancer in individual
ES2244417T3 (es) * 1999-04-09 2005-12-16 Rigshospitalet Inhibidor de tejido de metaloproteasa de matriz tipo-1 (timp-1) como un marcador de cancer.
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
DE60237969D1 (de) * 2001-04-24 2010-11-25 Bayer Corp Menschliche antikörper gegen timp-1
MXPA05005160A (es) * 2002-11-15 2005-07-22 Genmab As Anticuerpos monoclonales humanos contra la cd25.
US20040157278A1 (en) * 2002-12-13 2004-08-12 Bayer Corporation Detection methods using TIMP 1
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AU2004259398A1 (en) * 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
JP2007528721A (ja) * 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−２リガンド
EP1631315B1 (de) 2003-09-24 2014-07-30 Millennium Pharmaceuticals, Inc. Antikörper die zu humanen cxcr3 binden
EP1720907B1 (de) * 2004-02-06 2015-04-08 MorphoSys AG Humane anti-cd38-antikörper und anwendungen dafür
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
US20080019910A1 (en) * 2004-03-30 2008-01-24 Romer Maria U Cancer Treatment and Cancer Treatment Efficacy Prediction by Blocking and Detecting Protease Inhibitors
GB0420771D0 (en) * 2004-09-17 2004-10-20 Randox Lab Ltd Antibody
EP1888647A2 (de) * 2005-05-24 2008-02-20 MorphoSys AG Gewinnung und profiling von vollständig humanen, von hucal gold®-abgeleiteten therapeutischen antikörpern spezifisch für humanes cd38
JP5142458B2 (ja) * 2005-06-30 2013-02-13 キヤノン株式会社 標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法
TWI428444B (zh) 2005-10-12 2014-03-01 Morphosys Ag 由全長人類ＨｕＣＡＬ ＧＯＬＤ-衍生之對人類ＣＤ３８有特異性之治療抗體之產生及鑑定
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5368798B2 (ja) 2005-10-31 2013-12-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断し処置するための組成物および方法
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
US8003620B2 (en) 2006-08-04 2011-08-23 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
EP1997830A1 (de) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
CA2700293A1 (en) * 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US7892760B2 (en) * 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
AU2009237662A1 (en) * 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
PL2328616T3 (pl) * 2008-08-05 2015-10-30 Novartis Ag Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
JP5836125B2 (ja) 2008-10-16 2015-12-24 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
EP2230251A1 (de) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antikörper, die speziell im Koronarplaque aktiv sind und Verfahren zur ihrer Identifizierung
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
ES2728115T3 (es) * 2009-10-30 2019-10-22 Janssen Biotech Inc Antagonistas de IL-17A
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2859493A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
EP2911691B1 (de) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
BR112015023699A2 (pt) * 2013-03-15 2017-07-18 Intermune Inc método de determinação de um nível de expressão de uma proteína marcadora de doença pulmonar fibrótica, método de determinação se um indivíduo tem ou está em risco de desenvolvimento de uma doença pulmonar fibrótica, método de determinação se um paciente de doença pulmonar fibrótica está em risco de progressão da doença pulmonar fibrótica, método de determinação de uma atividade de doença pulmonar fibrótica em um paciente, e método de tratamento de uma doença pulmonar fibrótica em um indivíduo em necessidade do mesmo
WO2015067277A1 (en) 2013-11-07 2015-05-14 University Of Copenhagen Timp-1 binding partner
AU2019245285A1 (en) * 2018-03-30 2020-11-12 Eureka Therapeutics, Inc. Constructs targeting CD22 and uses thereof
JP2022548627A (ja) * 2019-09-16 2022-11-21 ノバルティス アーゲー 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK169987D0 (da) 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
WO1991010741A1 (en) * 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5324634A (en) 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
EP0670849B1 (de) 1992-10-29 2003-08-27 Bayer Corporation Diagnostischer test spezifisch für die latente matrix metalloproteinase no. 9
JPH08134098A (ja) 1994-11-11 1996-05-28 Morinaga & Co Ltd ヒトｔｉｍｐ−１の高感度測定法
CA2354863A1 (en) 1998-10-02 2000-04-13 University Of Florida Prevention of adhesions
ES2244417T3 (es) 1999-04-09 2005-12-16 Rigshospitalet Inhibidor de tejido de metaloproteasa de matriz tipo-1 (timp-1) como un marcador de cancer.
DE60237969D1 (de) * 2001-04-24 2010-11-25 Bayer Corp Menschliche antikörper gegen timp-1

Also Published As

Publication number Publication date
US20140086935A1 (en) 2014-03-27
ATE484522T1 (de) 2010-10-15
US20070160614A1 (en) 2007-07-12
US20040105862A1 (en) 2004-06-03
CA2445168A1 (en) 2002-10-31
WO2002086085A3 (en) 2003-02-20
JP4993779B2 (ja) 2012-08-08
EP1381631A2 (de) 2004-01-21
US20110262429A1 (en) 2011-10-27
US7993849B2 (en) 2011-08-09
HK1061699A1 (en) 2004-09-30
US20130302340A1 (en) 2013-11-14
US7091323B2 (en) 2006-08-15
JP2009195233A (ja) 2009-09-03
US20090017037A1 (en) 2009-01-15
WO2002086085A2 (en) 2002-10-31
JP4406206B2 (ja) 2010-01-27
EP1381631B1 (de) 2010-10-13
US7432364B2 (en) 2008-10-07
EP1381631A4 (de) 2006-02-01
AU2002307494A1 (en) 2002-11-05
JP2004529647A (ja) 2004-09-30

Similar Documents

Publication Publication Date Title
DE60237969D1 (de) Menschliche antikörper gegen timp-1
HUS1700013I1 (hu) Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk
NO20080636L (no) Brukergrensesnitt for a opprette en regnearkdataoppsummeringstabell
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
ATE476444T1 (de) Antigene gegen das leberstadium von plasmodium
EA200100747A1 (ru) Способ востребования приобретателем исполнения обязательства, связанного с карточкой, и признания этого обязательства эмитентом
BRPI0416391A (pt) composições de limpeza
DE60137607D1 (de) Substituierte cyclohexene
ITTV20040159A1 (it) Sistema di consultazione e trattamento di informazioni dedicate all'escursionismo con l'impiego di hardware standard pda.
ATE374947T1 (de) Bestimmung freier fraktionen
Cole Simple answers to museum complexity.
Woo A Business Planning Process Model to Develope Successful Housing Project
Ayrton Building bridges: Sustainable development and corporate community investment.
장암 et al. BOOK & PEOPLE
TR200100219T2 (tr) IL-8 Reseptörü Antagonistleri
Stuut et al. Late Quaternary aridity changes on the southern hemisphere inferred from the marine sediment record off Namibia and Chile
Saito et al. Theoretical identification of the C_20 fullerene
Al-Tamimi The Illuminations of Jafra in the Poetry of Manasrah
자연과 et al. BOOK & PEOPLE
Herce et al. Interior versus surface solvation of ions--role of polarization
van Ast et al. Stakeholders Participation In The European Water Framework Directive
삼고 et al. Copyright (C) 2002 Nuri Media Co Ltd.
Lee et al. Analysis of Environment-friendly Characteristics in the Environment-friendly Housing Certification
Elder Wood: Chemically Modified
Micolich et al. Stacked Billiards: Examining the Effect of Soft-wall Potential Profile on Fractal Conductance Fluctuations